# Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

> **NCT03700320** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 744 (actual)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** Standard of Care (SOC) Migraine Preventive Medication
- **DRUG:** Atogepant

## Key facts

- **NCT ID:** NCT03700320
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-08
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-05-21
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700320, "Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03700320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*